Mayne Pharma Group (ASX:MYX) Pretax Margin %: 2.65% (As of Dec. 2025)


ASX:MYX Mayne Pharma Group Ltd ASX:MYX
51 GF Score
Price A$2.57
GF Value A$5.31
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Pretax Margin %?

Mayne Pharma Group ASX:MYX +7.53% 51 Pretax Margin % is 2.65% as of Dec. 2025. GuruFocus rates ASX:MYX with a GF Score™ of 51/100 and a GF Value™ of A$5.31 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 117 Medical Distribution companies, Mayne Pharma Group ranks worse than 89.74% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Mayne Pharma Group's Pre-Tax Income for the six months ended in Dec. 2025 was A$5.5 Mil. Mayne Pharma Group's Revenue for the six months ended in Dec. 2025 was A$209.3 Mil. Therefore, Mayne Pharma Group's pretax margin for the quarter that ended in Dec. 2025 was 2.65%.

The historical rank and industry rank for Mayne Pharma Group's Pretax Margin % or its related term are showing as below:

ASX:MYX' s Pretax Margin % Range Over the Past 10 Years
Min: -147.87   Med: -40.26   Max: 20.28
Current: -15.62


ASX:MYX's Pretax Margin % is ranked worse than
89.74% of 117 companies
in the Medical Distribution industry
Industry Median: 2.37 vs ASX:MYX: -15.62

Mayne Pharma Group  (ASX:MYX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Mayne Pharma Group Pretax Margin % Related Terms


Mayne Pharma Group Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Pretax Margin % Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65.92 -51.38 -147.87 -49.00 -20.49

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.99 -57.41 -6.94 -35.30 2.65

ASX:MYX vs MCK, COR, CAH: Pretax Margin % Comparison

For the Medical Distribution subindustry, Mayne Pharma Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group Pretax Margin % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Pretax Margin % falls into.


ASX:MYX
51GF Score
Mayne Pharma Group Ltd ASX:MYX
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Mayne Pharma Group's Pretax Margin for the fiscal year that ended in Jun. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-83.296/406.51
=-20.49 %

Mayne Pharma Group's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=5.538/209.334
=2.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of 2.65% mean?
Mayne Pharma Group (ASX:MYX) has a Pretax Margin % of 2.65% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #105 out of 117 companies in the Medical Distribution industry, placing it in the top 89.7%.
Is Mayne Pharma Group's Pretax Margin % too high?
Mayne Pharma Group's current Pretax Margin % is 2.65%. The Medical Distribution industry median Pretax Margin % is 2.37. Mayne Pharma Group's value of 2.65% is 11.8% above this industry median. Based on the distribution chart, Mayne Pharma Group ranks #105 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Pretax Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #105 out of 117 companies for Pretax Margin %. This places Mayne Pharma Group in the lower half of its industry. The industry median Pretax Margin % is 2.37. Mayne Pharma Group's value of 2.65% is 11.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Distribution company?
The median Pretax Margin % among Medical Distribution companies is 2.37, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current Pretax Margin % of 2.65% is 11.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Pretax Margin % is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Pretax Margin % is 2.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current Pretax Margin % is 2.65% and 11.8% above the Medical Distribution industry median of 2.37. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current Pretax Margin % is 2.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for ASX:MYX:

  • Pretax Margin %: 2.65%
  • GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
  • GF Score™: 51/100 with 3 warning signs
  • Industry Position: 11.8% above the Medical Distribution median (#105 of 117)

No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mayne Pharma Group Business Description

Other Exchanges MAYNF:USA
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score

Get the complete analysis for ASX:MYX

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.57
Price
A$5.31
GF Value